1Charles TE. The protein C pathway. Chest, 2003,124 ( Suppl3 ) : 26--32.
2Dahlbaek B. The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res, 1995,77 ( 1 ) : 1-43.
3Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem, 1976,251 (2) :355--363.
4王振义,李家增,阮长耿.血栓与止血学.2版.上海:上海科学出版社,1995,91-94.
5Kisiel W. Human plasma protein C: Isolation, characterization, and mechanisms of activation by α-thrombin. J Clin Invest, 1979, 64(3 ) :761--769.
6Marlar RA, Griffin JH. Deficiency of protein C inhibitor in combined factor Ⅴ/Ⅷ deficiency disease. J Clin Invest, 1980, 66 (5) :1186--1189.
7Michalski C, Bal F, Bumouf T, et al. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma. Vox Sang, 1988,55 (4) :202--210.
8Radosevieh M, Zhou FL, Huart JJ, et al. Chromatographic puri-fication and properties of a therapeutic human protein C concentrate. Journal of chromatography B ,2003,790(1-2) :199--207.
9Nakamura S, Sakata Y. lmmunoaffinity purification of protein C by using conformation-specific monoclonal antibodies to protein Ccalcium ion complex. Biochim Biophys Acta, 1987,925 (2) :85-93.
10Regnault V, Rivat C, Pfister M, et al. Monoclonal antibodies a-gainst human plasma protein C and their uses for immunoaffinity chromatography. Thromb Res, 1991,63 (6) :629-640.
